Loading...

RemeGen Co., Ltd.

9995.HK•HKSE
Healthcare
Biotechnology
HK$55.55
HK$-3.65(-6.17%)

RemeGen Co., Ltd. (9995.HK) Stock Overview

Explore RemeGen Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.6/100

Key Financials

Market Cap38B
P/E Ratio-18.53
EPS (TTM)$-2.98
ROE-0.58%

AI Price Forecasts

1 Week$53.08
1 Month$42.95
3 Months$16.32
1 Year Target$12.22

9995.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of RemeGen Co., Ltd. (9995.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $12.22.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -18.53 and a market capitalization of 38B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for 9995.HKStats details for 9995.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 9995.HKAnalyst Recommendations details for 9995.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

CEO

Jianmin Fang

Employees

2,999

Headquarters

58 Middle Beijing Road, Yantai

Founded

2020

Frequently Asked Questions

;